login
  • SUBSCRIBER
  • User Name
  • Password
  • Remember Me
ad
20 Sep 2019, 11:41 HRS IST
|
  • PTI
CLOSE
RBI is more than autonomous in terms of decision making: RBI governor Shaktikanta Dasgovernor Shaktikanta Das AP
BACK
NEXT
  • Press Release


Source:Taj Pharmaceuticals Ltd
Category:Medical and Health Care
HC Disposed 'Copycat Drug' Claims and all Accusations Dropped Between Emcure Pharmaceuticals and Taj Pharmaceuticals
26/04/2016

HC Disposed 'Copycat Drug' Claims and all Accusations Dropped Between Emcure Pharmaceuticals and Taj Pharmaceuticals

MUMBAI, April 26,2016/PRNewswire/ -

All Allegations of 'Spurious Drugs' Disposed Between the two Pharma Companies as Sales of Licensed Bio-Similar Found 

After a heated few weeks at Taj Pharmaceuticals Ltd. and raised questions related to Counterfeit Carmustine 100mg Injections; all the allegations have been dropped by Emcure Pharmaceuticals for their brand misuses. The Hon'ble High Court, Justice Gautam Patel during hearing from both companies, guided the difference between generic and brands on medicines to the present counsels. After a considerable amount of evidence filed by both companies, it was concluded that, the counterfeit allegations were mislead by an Israeli firm Raz Pharmaceuticals to trigger Emcure for this suit; creating an immense concern to judiciary system and both parties involved in the Carmustine Injections business. However, after it was identified that in-fact Taj Pharmaceuticals supplies a generic version of the same drug through its licensed associate Therdose Pharma Pvt. Ltd, the confusion related to sales of 'spurious, illicit drugs' was cleared and no such claims stood relevant after Taj Pharmaceuticals' reply, and after licenses were presented for this matter. After the reply by Taj Pharma; it was observed that; both companies were engaged with supply of same active ingredient 'carmustine' in the injection; which is used in the treatment of patients diagnosed with cancer, lymphoma and tumors.

     (Photo: http://photos.prnewswire.com/prnh/20160426/10144860 )

Senior counsel Dinyar Madon represented Taj Pharma; he outlined issues related to US FDA failures of Emcure Pharmaceuticals in March 2016, as a possible motive behind claims. However, setting aside all contentions, both companies agreed to protect intellectual property in question, follow FDA norms and disposed-off the matter since public health has been at question and a great deal of controversy between both the companies are related to this matter; as the companies were dealing with the same injection with main active ingredient 'carmustine'. Hon'ble High Court Justice Gautam Patel has clearly said in the judgment "There has been in the past great deal of controversy between the Emcure and Taj Pharma. I cannot within the frame of a civil suit address the grievances."

Living up to the 'Make in India' initiative, India always remains the prime choice of access to life saving drugs at an affordable prices.

About Taj Pharma Group 

Taj Pharma Group is one of the leading generic pharmaceutical company in India. We hold top positions in different established markets and are building a strong presence in many emerging generics markets. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products.

Media Contact:
Shantanu Singh
s.k.singh@tajpharma.com
+91-22-2637-4592
Executive Director, Taj Pharmaceuticals Ltd.

CONTACT:
Media contact details:
 Bookmark with:   Delicious |  Digg |  Reditt |  Newsvine
  • Disclaimer:PTI takes no editorial responsibility for press releases.
    • arrow  Press Releases
  • pti